Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044544 | 0.80 | DRD2 (0.53) | DRD1CHRNA7ALDH1A1HPGDMTNR1A | |
| SCHEMBL21753264 | 0.78 | ADRA2A (0.51) | DRD1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL26922682 | 0.76 | GFER (0.40) | POLBDRD1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL31324605 | 0.76 | CYP1A2 (0.40) | POLBDRD1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL26650150 | 0.76 | CYP1A2 (0.40) | POLBDRD1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL16624042 | 0.75 | ASIC3 (0.50) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL30468429 | 0.74 | GAA (0.50) | DRD1ALDH1A1HPGDMTNR1AMTNR1B | |
| SCHEMBL227544 | 0.74 | GAA (0.50) | DRD1ALDH1A1HPGDMTNR1AMTNR1B | |
| SCHEMBL25899778 | 0.74 | MAOB (0.55) | EIF2AK2 | |
| Hydrochloric Acid SCHEMBL17965627 | 0.74 | ASIC3 (0.49) | CHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-01 | — | — | US | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | BACE1, BACE2, BCHE | POLB 3177/4885DRD1 2004/4885CHRNB2 484/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | POLB 3177/4885DRD1 2004/4885CHRNB2 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.